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Sonic hedgehog (Shh) signaling is critical in develop-
ment and oncogenesis, but the mechanisms regu-
lating this pathway remain unclear. Although protein
phosphorylation clearly affects Shh signaling, little is
known about phosphatases governing the pathway.
Here, we conducted a small hairpin RNA (shRNA)
screen of the phosphatome and identified Eya1 as
a positive regulator of Shh signaling. We find that
the catalytically active phosphatase Eya1 cooper-
ates with the DNA-binding protein Six1 to promote
gene induction in response to Shh and that Eya1/
Six1 together regulate Gli transcriptional activators.
We show that Eya1, which is mutated in a human
deafness disorder, branchio-oto-renal syndrome, is
critical for Shh-dependent hindbrain growth and
development. Moreover, Eya1 drives the growth of
medulloblastoma, a Shh-dependent hindbrain tu-
mor. Together, these results identify Eya1 and Six1
as key components of the Shh transcriptional
network in normal development and in oncogenesis.
INTRODUCTION
Shh is a key regulator of mammalian development, functioning
as both a mitogen and morphogen (Ingham et al., 2011). Dysre-
gulated Shh signaling results in awide variety of devastating birth
defects and cancers (Cohen, 2012; Nieuwenhuis and Hui, 2005;
Traiffort et al., 2010), so understanding the mechanisms of Shh
signaling has been a major goal in developmental and cancer
biology. Shh initiates signaling by binding to its receptor Patched
(Ptch1). In the absence of ligand, Ptch1 inhibits Smoothened
(Smo), a potent pathway activator. Upon Shh binding, Ptch1
no longer represses Smo. Once de-repressed, Smo enhances
Gli transcriptional activators and inhibits Gli transcriptional re-
pressors and so alters programs of gene expression.
The mechanisms whereby activated Smo signals to Gli tran-
scription factors are not yet understood. Protein phosphorylation22 Developmental Cell 33, 22–35, April 6, 2015 ª2015 Elsevier Inc.and dephosphorylation regulate multiple physiological func-
tions, and several screens have identified kinases involved in
the Shh pathway (Evangelista et al., 2008; Hillman et al., 2011;
Jacob et al., 2011; Varjosalo et al., 2008). However, the role of
phosphatases in Shh signaling is largely unexplored. We con-
ducted a small hairpin RNA (shRNA) screen to discover phos-
phatases in the Shh signaling pathway and identified Eya1 as a
positive regulator of this pathway. Eya1 is a phosphotyrosine
phosphatase that is mutated in branchio-oto-renal syndrome
(Abdelhak et al., 1997; Li et al., 2003; Rayapureddi et al., 2003;
Tootle et al., 2003; Xu et al., 1999). Eya1 dephosphorylates
histone variant H2AX and thereby affects DNA repair and cell
survival (Cook et al., 2009). In addition, catalytically active Eya1
interacts with Six family transcription factors to regulate gene
expression during development (Rebay et al., 2005; Tadjuidje
and Hegde, 2013). Both Eya and Six family members have
been implicated in tumor proliferation and progression (Christen-
sen et al., 2008; Pandey et al., 2010; Patrick et al., 2013).
Here we demonstrate that catalytically active Eya1, and its
binding partner Six1, function as transcriptional regulators in
Shh signaling pathways. Eya1 and Six1 alter the equipoise be-
tween Gli activators and repressors following Shh stimulation,
and so determine the ensuing biological response. Therefore
Eya1 is required for Shh-regulated proliferation and morphogen-
esis during hindbrain development. Constitutive activation of the
Shh pathway in neural precursors of the hindbrain causes me-
dulloblastoma, a cerebellar cancer that is the most commonma-
lignant brain tumor in children (Goodrich et al., 1997). We show
that Eya1 is preferentially expressed in Shh-subtype medullo-
blastomas and fosters tumor growth. Together these findings
identify a critical role for Eya1 and its partner Six1 in promoting
Shh-dependent transcription and suggest that Eya1 represents
a propitious therapeutic target in medulloblastoma.RESULTS
Identification of Eya1 as a Regulator of Shh Signal
Transduction by RNAi
To identify phosphatases regulating the Shh signaling pathway,
we conducted an shRNA screen that encompassed 320 gene
targets (Table S1). The screen was conducted in ShhLightII
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Figure 1. shRNA Screen to Identify Phosphatases in Shh Signaling
(A) SL2 cells were infected with virus encoding a single shRNA targeting 1 of 320 genes; infected cells were selected with puromycin and stimulated with
Shh-conditioned media, SAG, or vehicle control, and Gli-responsive luciferase activity was then measured.
(B) Primary screen average Firefly/Renilla luciferase values confirm Shh pathway activation by Shh and SAG (n = 1,720 wells, *p < 0.01, error bars = SEM).
(C) Replicate Firefly/Renilla luciferase values were averaged for each shRNA and converted to their natural log value.
(D) Primary screen robust Z score results. Genes with two or more hairpins giving results less than 1.5 or greater than 1.5 qualified as hits.
(E) A subset of hits from the primary screen were re-screened. Firefly/Renilla luciferase values were normalized to median Firefly/Renilla luciferase value of
negative control shRNAs. Values greater than 4-fold of the median response (above the black line) or less than 25% of the median response qualified as hits. Red
squares indicate values corresponding to an shRNA targeting Smo, and yellow circles indicate values corresponding to an shRNA targeting Eya1.
(F) Affymetrix array of medulloblastomas reveal a significant increase in Eya1 expression in the Shh subtype compared toWNT, group 3, or group 4 (p < 0.0001 by
ANOVA).
(G) An shRNA targeting Eya1 blocks SAG-mediated induction of Firefly/Renilla luciferase (n = 4,*p < 0.05, **p < 0.01, error bars = SEM; NS, not significant
[p > 0.05]).
(H) Eya1 shRNA blocks SAG-mediated induction of Gli1 mRNA (n = 5, *p < 0.05, **p < 0.01, error bars = SEM).
(I) Induction of Gli1 protein is blocked by shRNAs targeting Eya1. Actin = loading control.
(J) Induction of Gli1 protein is blocked by an Eya1 shRNA (n = 8,*p < 0.05, **p < 0.01, error bars = SEM).
(legend continued on next page)
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(SL2) fibroblasts, NIH 3T3 cells stably expressing a Gli-depen-
dent firefly luciferase reporter gene and a constitutive Renilla
luciferase gene (Taipale et al., 2000). To distinguish phospha-
tases that function in the pathway between Ptch1 and Smo
from those that function downstream of Smo, cells were stimu-
lated with full-length Shh ligand, which binds Ptch1, with a direct
Smo agonist (SAG) (Chen et al., 2002), or with vehicle control
(Figure 1A). Data from the primary screen indicate that both
Shh and SAG successfully stimulate the pathway (Figures 1B
and 1C). We identified as potential hits those genes for which
multiple targeting shRNAs achieved a robust Z score greater
than 1.5 (Figure 1D; Table S2), and we carried out a secondary
screen to validate these hits (Figure 1E). The secondary, more
rigorous screen identified genes for which two or more targeting
sequences altered Shh responses by more than 4-fold.
Several phosphatases previously implicated in Shh signaling,
including catalytic and regulatory subunits of Pp2a, were identi-
fied in our screens (Hillman et al., 2011; Nybakken et al., 2005)
(Table S3). None of the phosphatases tested differentially
affected signaling initiated by Shh and signaling initiated by
SAG, suggesting that the identified phosphatases function
downstream of Smo activation (Table S3). Among the genes
recognized in our screen (Table S4), three phosphatases
(Ppm1a, Eya1, and Eya2) are reported to be differentially ex-
pressed in Shh-subtype medulloblastoma compared with other
medulloblastoma subtypes (Kool et al., 2008; Northcott et al.,
2011; Thompson et al., 2006), suggesting that they are likely to
be biologically important for Shh signaling. Analysis of gene
expression databases encompassing more than 70 medullo-
blastomas tumors (Robinson et al., 2012) confirmed that Eya1
expression is consistently higher in Shh subtype medulloblas-
tomas than in other medulloblastoma subtypes (Figure 1F). We
verified that shRNAs targeting Eya1 and Smo efficiently knock
down the target mRNA and that shRNAs targeting Eya1 reduce
Eya1 protein levels (Figures S1A–S1C), while shRNAs intended
to target Eya2 do not affect Eya2 levels and instead reduce
Eya1 mRNA expression (Figures S1D and S1E). We therefore
focused our studies on Eya1.
Multiple, validated shRNAs targeting Eya1 clearly inhibit Shh
signaling in SL2 cells using several readouts of pathway activa-
tion, including SAG-mediated induction of Gli-responsive firefly
luciferase (Figures 1G and S1F) and induction of the target genes
Gli1 and Ptch1 as measured by qPCR and by western blot (Fig-
ures 1H–1K and S1G–S1I). Strikingly, Eya1 knockdown inhibits
Shh pathway to a similar degree as does Smo knockdown.
This is a selective effect on Shh responses, as Eya1 knockdown
in SL2 cells does not alter platelet-derived growth factor (PDGF)-
induced c-fos expression (Figure S1J). Furthermore, under the
conditions tested, Eya1 knockdown did not affect cell number
overall or alter apoptosis or proliferation as measured by TUNEL
staining and by phospho-histone H3 (pH3) staining, respectively
(Figures S1K and S1L). Together these data indicate that
Eya1 shRNAs exert a selective effect on Shh-responsive gene
induction.(K) An shRNA targeting Eya1 blocks induction of Ptch1 mRNA (n = 5, *p < 0.05,
(L and M) Gli1 (L) and Ptch1 (M) mRNA induction are reduced in Eya1/ MEFs c
(N and O) Gli1 mRNA (N) and Ptch1 mRNA (O) in Eya1/ and Eya1+/+ MEFs,
bars = SEM).
24 Developmental Cell 33, 22–35, April 6, 2015 ª2015 Elsevier Inc.Studies in mouse embryonic fibroblasts (MEFs) fromwild-type
and Eya1/ littermates confirm that Eya1 is needed for Shh-
dependent signaling, as demonstrated by SAG-induced expres-
sion of Gli1 and Ptch1 (Figures 1L and 1M, respectively).
Re-expression of wild-type Eya1 in mutant MEFs restores
SAG-dependent Gli1 and Ptch1 regulation, while a mutant
form of Eya1 without phosphatase activity (D327A) does not do
so, indicating that catalytically active Eya1 is required for Shh
signaling (Figures 1N, 1O, S1M, and S1N). We verified that
endogenous Eya1 is catalytically active in the cells tested, as
Eya1/ MEFs exhibit increased tyrosine phosphorylation of
the substrate H2AX (Cook et al., 2009), and knockdown of
Eya1 increases H2AX phosphorylation in SL2 cells (Figure S1O).
However, stimulation with a Smo agonist does not alter H2AX
expression or phosphorylation status, suggesting that phospha-
tase activity of Eya1, not changes in H2AX phosphorylation per
se, are required for Eya-mediated Shh signaling (Figure S1P).
The catalytically active phosphatase Eya1 interacts with two
DNA-binding proteins, Six and Dach, to regulate multiple devel-
opmental processes (Li et al., 2003). We screened shRNAs tar-
geting diverse members of the Six and Dach protein families in
SL2 cells, and found that Six1 is both expressed in these cells
and required for Shh pathway activation (Figures 2A and S2A).
Two distinct shRNAs that target Six1 (Figures 2B–2D) reduce
Gli1 induction in response to SAG to the same extent as Eya1
shRNAs (Figures 2E–2G and S2B); furthermore, simultaneously
knocking down Eya1 and Six1 does not additionally impinge on
the response to SAG (Figure 2G). When introduced into SL2
cells, HA-tagged Eya1 is localized throughout the cell but be-
comes localized to the nucleus when co-expressed with Six1
(Figure 2H). Together, these data are consistent with a model
wherein Eya1 and Six1 work together in the nucleus to regulate
Shh signal transduction.
Six1 contains aDNAbinding domain and binds directly to tran-
scription promoter sites, including the Six4 promoter (Liu et al.,
2010a). However, Six1 does not contain an activation domain,
and so catalytically active Eya1 or another co-factor is required
to alter gene transcription (Wu et al., 2013). We analyzed expres-
sion of Six4, a known Six1-target gene (Liu et al., 2010b), in SL2
cells and in MEFs. Stimulation with SAG increases mRNA levels
of Six4, and this response depends on Six1, Eya1, and the Shh
signaling receptor Smo (Figure 2I) but does not require Gli2,
the canonical Shh-pathway transcription factor (Figures 2J and
S2C). Chromatin immunoprecipitation (ChIP) studies verified
that Six1 interacts with the Six4 promoter in SL2 cells (Figure 2K).
Taken together, these data indicate that Eya1 cooperates
with Six1 to initiate transcription of Shh-dependent genes,
including Six4.
Eya1 and Six1 Act in the Shh Signaling Pathway between
Smo and Sufu
Primary cilia are essential for Shh signaling, and mutants lacking
cilia do not respond to pathway stimulation (Goetz and Ander-
son, 2010). Eya1/ cells are ciliated, indicating that Eya1 is**p < 0.01, error bars = SEM).
ompared with Eya1+/+ littermates (n = 3, *p < 0.05, error bars = SEM).
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Figure 2. Six1 Promotes Shh Pathway Activation
(A) An shRNA targeting Six1, but not Six4, blocks induction of Firefly/Renilla luciferase (n = 3); no puromycin selection in these studies (n = 4, *p < 0.05, error
bars = SEM).
(legend continued on next page)
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Figure 3. Eya1 and Six1 Function in Shh
Transduction between Smo and Sufu
(A) Eya1/ granule cell precursors are ciliated.
g-Tubulin (red) marks basal bodies and acetylated-
a-tubulin (green) marks the ciliary axoneme; nuclei
are visualized by DAPI (blue); the scale bar repre-
sents 10 mm.
(B) Stable cell lines with Sufu knockdown (Sufu KD)
or Gli2 overexpression (Gli2-SL2) have constitu-
tively elevated levels of Gli1 protein (see lanes 1, 3,
and 5); actin = loading control.
(C) Eya1 and Six1 shRNAs do not reduce Gli1
protein levels in Sufu KD cells (actin = loading
control).
(D) Eya1 and Six1 shRNAs do not reduce Gli1
mRNA in Sufu KD cells (n = 5; n = 3 Six1-1).
(E) Eya1 and Six1 shRNA do not alter Gli1 protein in
Gli2-SL2 cells (actin = loading control).
(F) Eya1 or Six1 shRNA do not reduce Gli1
mRNA in Gli2-SL2 cells (n = 5, n = 2 Six1-1, error
bars = SEM).not necessary for ciliogenesis (Figure 3A). Because both Eya1
and Six1 are required for activation of the pathway by SAG, a
Smo agonist, these components must act in the pathway down-
stream of Smo activation.
In the absence of Shh stimulation, Gli transcription factors
interact with Sufu. After Smo activation, Gli transcription factors
are released by Sufu and traffic to the nucleus, where they acti-
vate or repress gene transcription. To investigate whether Eya1
and Six1 function upstream of Sufu and of Gli transcription fac-
tors we expressed shRNA against Sufu in SL2 cells (Figure S3A)
or expressed a truncated constitutively active Gli2 and thereby
activated the Shh pathway (Figure 3B). Eya1 and Six1 shRNAs
do not affect the constitutive activation of the pathway induced
by Sufu loss or by Gli2 expression (Figures 3B–3F, S3A, and
S3B). Together, these data demonstrate that Eya1 and Six1
function upstream of Sufu and of Gli2 to regulate Shh signaling
activity.
Like Eya1 and Six1, Nrp1 and Nrp2 are positive regulators of
Shh signaling that mediate signal transduction between Smo
and Sufu (Hillman et al., 2011). Shh pathway activation both(B and C) Six1 shRNAs (Six1-1 and Six1-2) effectively knock down Six1 mRNA (B) (n = 4 or 5, *p < 0.05, er
(actin = loading control).
(D) Quantification of Six1 protein normalized to actin (n = 6, *p < 0.05, error bars = SEM).
(E) Six1 knockdown blocks Gli1 protein induction by SAG (actin = loading control).
(F) Quantification of Gli1 induction (n = 6, *p < 0.05, error bars = SEM).
(G) Six1 knockdown blocks Gli1 mRNA induction (n = 4 or 5, *p < 0.01, error bars = SEM).
(H) Eya1-HA is located throughout the cell; co-transfection of Eya1-HA and Six1 results in nuclear localizatio
represents 50 mm.
(I) Six4 mRNA is induced by SAG in SL2 cells; induction requires Smo, Eya1, and Six1, as shown by knoc
*p < 0.05, error bars = SEM).
(J) Gli1 and Six4 mRNA in control and Gli2/ MEFs (n = 3, *p < 0.05, error bars = SEM). Gli2 is required for
(K) ChIP of SAG-stimulated or control SL2 cells (following knockdown of LacZ-control, Smo, Eya1, or Six1) wa
Six4 or Hoxd10 promoter. Six1 interacts with Six4 promoter, not with negative control Hoxd10. Six4 promote
Enrichment for Six4 relative to Hoxd10: *p < 0.05 by Z test with Bonferroni correction.
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however Nrp1 is not a direct target of Gli
transcription factors suggesting that Shhmight regulate transcription by additional mechanisms other
than Gli transcription factors (Hillman et al., 2011; Hochman
et al., 2006).
Knockdown of Eya1 or Six1 reduce Nrp1 and Nrp2 (Figures
4A–4E) in both unstimulated and SAG-stimulated cells, indi-
cating Eya1 and Six1 are required for both basal and Shh-
induced Nrp gene expression. Similarly expression of Nrp1
mRNA is reduced in Eya1/ MEFs (Figure 4F), and catalytically
active Eya1, but not inactive D273A Eya1, increases Nrp1
expression following SAG stimulation (Figure S4). In contrast,
the transcription factor Gli2 is not required for SAG-dependent
Nrp gene induction (Figure 4G). Thus transcription factor Six1
and catalytically active co-activator Eya1 rather than Gli tran-
scriptional activators control Shh-regulated Nrp1 expression,
thereby conveying signal transduction between Smo and Sufu.
Eya1, Six1, and Nrps Do Not Affect Formation of Gli3
Repressors
Shh pathway activity enhances expression and function of Gli-
transcriptional activators, and concurrently inhibits formation ofror bars = SEM) and reduce Six1 protein levels (C)
n of Eya1 in SL2 cells, anti-HA (green); the scale bar
kdown of LacZ-control, Smo, Eya,1 or Six1 (n = 3,
induction of Gli1 but not Six4.
s done using antibody to Six1, followed by qPCR for
r interaction is reduced by Six1 or Eya1 knockdown.
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Figure 4. Eya1 and Six1 Regulate Nrp Expression
(A) shRNAs targeting Eya1 and Six1 reduce Nrp1 and Nrp2 protein levels in unstimulated and SAG-stimulated SL2 cells (actin = loading control).
(B) Quantification of Nrp1 (n = 3 or 4, *p < 0.05, error bars = SEM).
(C) Quantification of Nrp2 (n = 3, *p < 0.05, error bars = SEM).
(D and E) shRNAs targeting Eya1 and Six1 reduce Nrp1mRNA (n = 5 or 6, *p < 0.05, error bars = SEM) and Nrp2mRNA (n = 4 or 5, *p < 0.05, error bars = SEM).
(F and G) SAG-induced expression of Nrp1 is prevented in Eya1/ MEFs (F) but not in Gli2/ MEFs (G) (n = 3, *p < 0.05, error bars = SEM).
(H) shRNA targeting Nrp1 plus shRNA targeting Nrp2 reduce Gli1 protein following Shh stimulation (actin = loading control).
(I) Eya1 knockdown does not alter SAG-induced changes in Gli3R formation; Smo knockdown does do so.
(J) Western blot quantification of Gli3R (n = 3, *p < 0.05, error bars = SEM).
(K) shRNA targeting Nrp1 plus shRNA targeting Nrp2 does not alter Gli3R formation following Shh stimulation (actin = loading control).
(L) Western blot quantification of Gli3R (n = 3, *p < 0.05, error bars = SEM).Gli transcriptional repressors (Blaess et al., 2006;Bok et al., 2007;
Wang et al., 2000). Eya1 and Six1 are required for transcription
mediated by Gli-activator species, as assessed by Gli1 gene
induction. Similarly, Nrp1 and Nrp2 regulate Gli1 induction in
response to pathway stimulation (Figure 4H). However, we find
that Eya1 and Nrps are not necessary for Shh-dependent inhibi-
tion of Gli3 repressors (Gli3R). Eya1 knockdown, or knockdown
of Nrp1 and Nrp2, does not alter SAG-induced processing of
Gli3 to form the 83kD amino-terminal repressor fragment, Gli3R
(Figures 4I–4L). In contrast, knockdown of Smo prevents bothGli3R inhibition and SAG-stimulated Gli1 induction. These data
indicate that Eya1 and Nrps are required selectively for Smo-
mediated Gli activator functions and not for regulation of Gli3R,
and so link Eya1 and Nrps in a pathway that differentially modu-
lates Shh signal transduction.
Eya1 Promotes Shh Signaling in Hindbrain Development
and in Tumorigenesis
Eya1 and Six1 are expressed in Shh-responsive cells within the
otic vesicle, and Eya1/, Six1/, and Shh/ mutants exhibitDevelopmental Cell 33, 22–35, April 6, 2015 ª2015 Elsevier Inc. 27
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Figure 5. Eya1 and Shh Signaling in Devel-
oping Otic Vesicle
(A) Eya1/ otic vesicles at E10.5 have reduced
Eya1, Gli1, and Ptch1 expression by in situ hy-
bridization (OV, otic vesicle; OE, otic epithelium;
scale bar represents 50 mm), but expression
of Gata3 is evident in ventral cells of Eya1/ otic
vesicles (Zou et al., 2006).
(B) E10.5 Eya1+/ otic vesicles have increased
apoptosis by TUNEL staining (green); nuclei
stained by DAPI (blue); the scale bar represents
50 mm. White arrows indicate TUNEL-positive
cells. Comparison of Eya1+/ and Eya1+//
Ptch1+/ mice.
(C) Percentage of otic vesicle cells that are TUNEL-
positive (n = 19 sections from two mutant and
two wild-type littermate mice, *p < 0.01, error
bars = SEM).similar otic vesicle phenotypes (Ozaki et al., 2004; Xu et al., 1999;
Zheng et al., 2003; Zou et al., 2006). To investigate a role for Eya1
in Shh signaling within the auditory system, we analyzed expres-
sion of the Shh target genesGli1, and Ptch1, in Eya1/ otic ves-
icles (Xu et al., 1999). Eya1, Gli1, and Ptch1 are all expressed in
the ventral portion of the otic vesicle in wild-type animals, and
expression of these genes is decreased in Eya1/ otic vesicles,
demonstrating that loss of Eya1 results in reduced Shh signaling
in vivo (Figures 5A and S5).
Cell death is increased in Eya1/ otic vesicles (Xu et al., 1999;
Zou et al., 2006), and this phenotype is also observed in Eya1+/
otic vesicles (Figures 5B, center panel, and 5C). We find that gain
of function in the Shh pathway reverses the apoptotic phenotype
of Eya1+/mice, as demonstrated by comparing TUNEL-positive
cells in Eya1+/ and Eya1+/;Ptch1+/ otic vesicles (Goodrich
et al., 1997) (Figures 5B, right panel, and 5C). These data demon-
strate a genetic interaction between Eya1 and Shh signaling
in vivo and indicate that Eya1 plays a critical role in Shh-depen-
dent hindbrain development.
Shh has a well-recognized role as a mitogen for granule
cell precursor proliferation in the developing external granule
cell layer (EGL) of the cerebellum (Dahmane and Ruiz i Altaba,
1999; Wallace, 1999; Wechsler-Reya and Scott, 1999). Eya1 is
expressed in the developing cerebellum, and levels decrease
during postnatal development (http://www.cdtdb.neuroinf.jp).
In the early cerebellum, Eya1 mRNA is evident both in Purkinje28 Developmental Cell 33, 22–35, April 6, 2015 ª2015 Elsevier Inc.cells and in granule cell precursors in the
EGL, an expression pattern similar to
that observed for Gli1 (Figures 6A–6C
and S6). We find that Gli1 levels
are reduced in Eya1/ cerebella, while
expression of Shh does not change (Fig-
ures 6A–6C). Consistent with our data in
fibroblasts, Eya1 is required for Gli activa-
tors but is not required for Gli3 repressor
formation in developing cerebellum
(Figure 6D). Importantly, the cerebellar
phenotype of Eya1/ embryos resem-
bles the phenotype observed at this age
with mutations in Gli2 or other mutationsthat cause loss of Shh activity (Corrales et al., 2004), with striking
reduction in granule cell precursor proliferation as assessed by
pH3 and Ki67 staining (Figures 7A–7C), without increased cell
death (Figures 7D and 7E). Eya1 fosters Shh responses during
embryonic and postnatal development of the cerebellum, as
granule cell precursor proliferation and Gli1, Nrp1, and Ptch1
expression are also dramatically decreased in Eya1+/ mice at
postnatal day 3 (Figures 7F–7I). Eya1 acts cell autonomously
within granule cell precursors to promote Shh responses, as
purified, cultured granule cell precursors that lack Eya1 do not
respond to exogenous Shh pathway agonists measured by in-
duction ofGli1, Ptch1, Six4, and Nrp1 (Figures 7J–7M). Together
these data demonstrate that Eya1 promotes Shh-dependent
signaling and proliferation in precursors of the developing
cerebellum.
Constitutive activation of Shh signaling in granule cell precur-
sors results in the cerebellar tumor, medulloblastoma (Goodrich
et al., 1997; Hallahan et al., 2004; Han et al., 2009). Heterozygous
mutations in Ptch1 in mice and in humans confer a high risk for
developing medulloblastoma (Goodrich et al., 1997). Strikingly,
the incidence of medulloblastoma is greatly decreased in mice
that are heterozygous for both Ptch1 and Eya1 compared to
Ptch1+/mice from the same colony (Figure 7N), providing in vivo
evidence that Eya1 promotes growth of these Shh-pathway-
dependent cerebellar tumors. Our lab recently generated cell
lines derived from medulloblastoma of Ptch1+/ mice that are
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Figure 6. Eya1 Promotes Shh Signaling in
Cerebellum
(A) Eya1 is expressed in Purkinje cells and granule
cell precursors in the EGL. In situ hybridization
of Eya1, Gli1, and Ptch1 in E18.5 Eya1+/+ and
Eya1/ cerebella; the scale bar represents 25 mm.
(B) Western blot of Gli1 in Eya1+/+ and Eya1/
E18.5 cerebellum.
(C) Gli1, Ptch1, and Shh mRNA levels in Eya1+/+
and Eya1/ cerebellum.
(D) Gli1 and Gli3 immunoblots of Eya1+/+ and
Eya1/ E18.5 cerebellar lysates. Eya1/ cere-
bella have decreased Gli1 protein with no change
in Gli3R levels.tumorigenic and retain Shh dependence in vitro (Shh-medullo-
blastoma or SMB cells; Zhao et al. unpublished observations).
Both Smo and Eya1 knockdown reduce Gli1 mRNA levels and
decrease viability of these SMB cells (Figures 7O and 7P),
indicating that Eya1, like Smo, functions cell autonomously to
promote tumor cell growth. Thus Eya1 provides a potential ther-
apeutic target for Shh-subtype medulloblastoma.
DISCUSSION
An unbiased shRNA screen of the phosphatome implicated
Eya1, a tyrosine phosphatase and transcriptional co-activator,
in Shh signaling. We find that Eya1 acts in concert with a collab-
orating transcription factor, Six1, to change gene expression.
Eya1, Six1, and a target gene, Nrp1, all function in the Shh
pathway between Smo and Sufu, and preferentially regulate Gli
activators rather than Gli repressors. In vivo, Eya1 is critical for
Shh-dependent development of the cerebellum and inner ear,
and Eya1 fosters growth of medulloblastoma, a Shh-pathway
dependent tumor. Thus, Eya1/Six1 function as transcriptional
regulators within the Shh pathway and alter the equipoise
between Gli activators and repressors during development and
oncogenesis.
Eya1 and Six1 Function Together to Regulate Shh Signal
Transduction
Previous studies demonstrate that Eya family members coop-
erate with DNA-binding proteins of the Six family to regulate
transcription (Li et al., 2003). In humans, heterozygous muta-
tions in Eya1 and Six1 cause branchio-oto-renal syndrome, in
which development of the inner ear, face, and kidneys is per-
turbed, resulting in deafness and impaired renal function (Koch-
har et al., 2007). Taken together, data that Eya1 facilitates Six1
binding to the Six4 promoter and that Shh-pathway stimulation
regulates Six4 expression, indicate that Shh fosters Eya1/Six1-
dependent transcription and thereby instigates signal transduc-Developmental Cell 33, 2tion. Eya and a Drosophila homolog of
Six, So, are part of the retinal determina-
tion gene network, a program critical for
eye development in Drosophila (Kumar,
2009). Interestingly, So was identified in
a genome-wide RNAi screen for compo-
nents of the Hh signaling pathway, sug-
gesting that Eya and Six family membershave an evolutionarily conserved role in Hh functions (Nybakken
et al., 2005).
Eya proteins contain a highly conserved C-terminal domain
called the Eya domain, which is necessary for Eya to bind Six.
The Eya domain contains a haloacid dehalogenase (HAD)
sequence motif that is necessary for tyrosine phosphatase
activity (Li et al., 2003; Rayapureddi et al., 2003; Tootle et al.,
2003). Missense Eyamutations that disrupt protein phosphatase
activity also impair the function of an Eya-So/Six complex
(Mutsuddi et al., 2005; Rayapureddi et al., 2003; Tootle et al.,
2003), but Eya1 dephosphorylation of H2AX does not depend
on Six (Cook et al., 2009; Krishnan et al., 2009). Thus Eya1 phos-
phatase can operate either independently or in concert with Six
familymembers. The data presented here indicate that Eya1 acts
together with Six1 to mediate Shh signal transduction and
demonstrate that Eya1 phosphatase activity is essential for this
function.
Eya1 and Six1 Regulate Nrp Gene Expression
A model for the roles of Eya1, Six1, and Nrp1/2 in Shh signal
transduction is shown as the graphical abstract. Genetic epis-
tasis experiments indicate that Eya1, Six1, and Nrp1/2 are all
positive regulators of Shh transduction, and function in the
signaling pathway between activated Smo and Sufu/Gli2. We
suggest that a major mechanism by which Eya1 and Six1 regu-
late Shh signaling is by controlling transcription of Nrp1 and
other target genes (Ahmed et al., 2012). Consistent with a para-
digm in which Eya1/Six1 collaborate to directly regulate Nrp
expression, Six1 binds to the Nrp1 promoter region by ChIP
analysis (Liu et al., 2010b). Intriguingly, Eya1 and Nrp1/2 regulate
Gli activator species but are not involved in generating the Gli3
repressor. These data suggest that the mechanisms regulating
Gli activators and repressors diverge from one another subse-
quent to Smo activation, and that Nrp1/2 function selectively in
the branch crucial for Gli activators. Recent studies indicating
that expression of Gli activators and repressors exhibit distinct2–35, April 6, 2015 ª2015 Elsevier Inc. 29
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dynamics during development (Junker et al., 2014) accord well
with the proposed model.
An uncoupling of Gli activator and Gli3R regulation has been
reported in mice with a null allele of Arl13b, a small GTPase of
the Arf/Arl family (Caspary et al., 2007). MEFs lacking Arl13b
have shorter cilia and abnormal localization of Smo, Gli2, and
Gli3 following pathway activation (Caspary et al., 2007; Larkins
et al., 2011). In contrast, absence of Nrp1/2 or of Eya1 do not
alter ciliary morphology (Figure 3) and (Hillman et al., 2011).
Although Arl13b preferentially affects Gli activators because of
its role in ciliogenesis, it appears that Nrp1/2 functions more
directly to liberate Gli activator from sequestration and promote
trafficking of Gli activator to nuclear DNA binding sites.
Significance of Eya1 in Shh Signaling in Hindbrain
Development and Cancer
We demonstrate that Eya1 is required for Shh signaling in NIH
3T3-derived cells and in MEFs in vitro, and we show that
Eya1 promotes Shh signaling in the developing brainstem and
hindbrain in vivo. In Eya1 mutants, Gli1 expression is decreased
in developing otic vesicle and cerebellum. The genetic interac-
tion between Eya1 and Ptch1 mutations in the otic vesicle,
and the phenotypic similarity of the Eya1 mutant cerebellum
to mutants with loss of Shh signaling, indicate that Eya1 is crit-
ical for multiple biological responses to Shh in the developing
hindbrain. However, Eya1 is not uniformly involved in Shh-
dependent responses. An early function for Shh signaling is
patterning of the developing spinal cord, but Eya1/ embryos
do not exhibit defects in spinal cord patterning (Figure S7).
Outside of the nervous system, Eya1 and Six1 function within
Shh-producing cells rather than Shh-responsive cells, so
Eya1/ lung tissue exhibits higher levels of Shh and of Gli1
compared with wild-type counterparts (El-Hashash et al.,
2011a, 2011b; Lu et al., 2013). Thus, unlike Ptch1 or Smo,
Eya1 is not a core component of the Shh signal transduction
pathway but is preferentially involved in a subset of Shh-depen-
dent functions in neural tissues.
Overexpression of Eya family members has been reported in
many human cancers, often accompanied by misregulation of
Six family members (Auvergne et al., 2013; Tadjuidje and Hegde,
2013). Neuropilins have also been implicated in growth of
multiple tumors, including medulloblastoma (Hayden Gephart
et al., 2013; Snuderl et al., 2013). Eya1 is highly expressed in hu-Figure 7. Eya1 Promotes Proliferation in Cerebellar Granule Cell Precu
(A) pH3 immunohistochemistry (red); nuclei stained with DAPI (blue) in Eya1+/+ a
represents 50 mm.)
(B) Quantification of pH3-positive cells per cerebellum (n = 3 per genotype, *p <
(C) Ki67-positive cells are reduced in Eya1/ E18.5 cerebella (n = 3 per genotyp
(D) TUNEL-positive cells (green) in Eya1+/+ and Eya1/ E18.5 cerebella. Nucl
represents 50 mm).
(E) Quantification of TUNEL-positive cells (n = 3 per genotype, error bars = SEM
(F) Quantification of pH3-positive cells in Eya1+/+ and Eya1+/ postnatal day 3 (P
(G and H) Western blot (G) and quantification (H) of Gli1 in P3 Eya1+/+ and Eya1+
(I) qRT-PCR of Gli1, Nrp1, and Ptch1 in Eya1+/+ and Eya1+/ P3 cerebellum (n =
(J–M) In culture, purified Eya1/ cerebellar granule cell precursors (from E18.5) do
qRT-PCR for (J) Gli1, (K) Ptch1, (L) Six4, and (M) Nrp1 (n = 3 per genotype, *p <
(N) Kaplan-Meier analysis of deaths due to medulloblastoma in Eya1+/ (N = 12)
(O) Smo and Eya1 shRNA reduce Gli1 mRNA in cultured mouse medulloblastom
(P) Smo and Eya1 shRNA reduces the viability of cultured mouse medulloblastomman Shh-subtype medulloblastoma (Figure 2) (Kool et al., 2008;
Northcott et al., 2011; Thompson et al., 2006), and Eya1 pro-
motes medulloblastoma growth both in vitro and in vivo. These
data raise the intriguing possibility that targeting Eya1 may pro-
vide an effective strategy for treating these cancers. Unlike many
transcriptional regulators, Eya1 has enzymatic activity and is
therefore a potentially druggable target. In addition, Eya proteins
belong to the small HAD family of phosphatases that possess an
uncommon catalytic domain. Targeting this infrequent catalytic
domain has allowed the development of specific Eya2 phospha-
tase inhibitors, suggesting that selectively targeting Eya1may be
feasible (Krueger et al., 2013). Although several promising small
molecule inhibitors of Smo can treat basal cell carcinoma and
medulloblastoma, not all patients respond consistently to Smo
inhibitors (Kool et al., 2014; Metcalfe and de Sauvage, 2011;
Rodon et al., 2014). Selective Eya1 inhibitors may provide an
effective alternative approach for blocking Shh signaling and
thereby treating these cancers.EXPERIMENTAL PROCEDURES
Animal Studies
All experimental procedures were done in accordance with National Institutes
of Health (NIH) guidelines and were approved by the Dana-Farber Cancer
Institute’s Institutional Animal Care and Use Committee. Eya1/ mice were
obtained from Pin-Xian Xu (Xu et al., 1999) and Ptch1+/ mice from Jackson
Laboratory (Goodrich et al., 1997). The morning of the day a vaginal plug
was detected was designated E0.5.Cell Culture and Constructs
SL2 cells were obtained from American Type Culture Collection and cultured
according to their recommendations. After introduction of pLKO.1 lentiviral
shRNAs, cells were selected for infection using puromycin (4 mg/ml), unless
otherwise noted. SMB cells were prepared from medulloblastoma tumors
of Ptch1+/ mice. These cells express Shh components and cell viability is
dependent on Shh pathway activity (Zhao et al., unpublished data).
Primary granule cell precursors were cultured from E18.5 cerebella as
described (Zhou et al., 2007). SMB cell viability was assayed using CellTiter96
Aqueous One Solution Cell Proliferation Assay (Promega). SL2 cells were
transfected using Fugene6 with mouse PiggyBac transposase and a trans-
poson encoding V5-Gli2 or GFP. The coding sequence from full-length Eya1
(Thermo Scientific Clone ID 6848408) was cloned into pcDNA3.1(+)-
KozakHAHA, and full-length Eya1 was cloned into pCMV-Sport6. Six1-
pCMV-Sport6 was obtained from Open Biosystems (Clone ID 4188451).
MEFs were cultured from E12 Eya1+/+ and Eya1/ littermates, or from
Gli2/ mice as described (Jozefczuk et al., 2012).rsors and in Medulloblastoma
nd Eya1/ E18.5 cerebellum. (Arrows indicate pH3-positive cells; scale bar
0.01, error bars = SEM).
e, *p < 0.01, error bars = SEM).
ei stained with DAPI (blue) (arrows indicate TUNEL-positive cells; scale bar
).
3) cerebellum (n = 3 per genotype, *p < 0.01, error bars = SEM).
/ cerebellum (n = 3 per genotype, *p < 0.01, error bars = SEM).
3 per genotype, *p < 0.01, error bars = SEM).
not respond to Shh-pathway stimulation with exogenous SAG as assessed by
0.01, error bars = SEM).
, Ptch1+/ (N = 64), and Eya1+//Ptch1+/ (n = 87) (p = 0.0062).
a cells (n = 4 to 5).
a cells (n = 3, *p < 0.01, error bars = SEM).
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Shh Ligand Preparation and Cell Stimulation
293FT cells were transfected with full-length Shh in pcDNA3 using Lipofect-
amine 2000, and Shh was prepared as described previously (Chan et al.,
2009; Witt et al., 2013). Confluent SL2 cells were stimulated with Shh
(300 ng/ml) or SAG (300 nM; Enzo Life Sciences) in DMEM with 0.5%
calf serum for 48 to 72 hr. Cells were stimulated with purified PDGF-BB
(100 ng/ml for 30 min) in the same media.
shRNA Screen and Analysis
pLKO.1 lentiviral shRNAs were from the Broad Institute RNAi Consortium
(TRC). SL2 cells were plated in 96-well plates, then each well was infected
with a single shRNA lentivirus. shRNAs targeting RFP, GFP, LacZ, and two
shRNAs targeting Smo were included on each plate as negative and positive
controls, respectively; duplicate plates were tested. Infected cells were
selected with 4 mg/ml puromycin, then cells were stimulated with Shh, SAG,
or vehicle for 72 hr, then lysed and tested. Luciferase assays were conducted
using a dual luciferase reagent (Promega #E1960) kit.
shRNAs with a Renilla luciferase value equal to zero were eliminated from
analysis. Firefly/Renilla luciferase ratios from duplicate wells were averaged
and average Firefly/Renilla luciferase ratios equal to zero were assigned
a value of 1 3 106. We calculated the robust Z score for each shRNA
([x  median]/[median absolute deviation]; median absolute deviation =
median {abs[x  median]} 3 1.4826) using the natural logarithm of all values.
For the primary screen, genes were considered hits if two or more targeting
shRNAs generated a robust Z score less than 1.5 or greater than 1.5 in
pathway stimulation conditions. In the secondary screen genes were consid-
ered hits if multiple shRNAs resulted in Firefly/Renilla luciferase values less
than 25% or greater than 400% of the median value of control shRNAs.
Screen analysis was conducted in Microsoft Excel (Microsoft Corporation)
and in MATLAB (The MathWorks).
Lentiviral Production
Virus containing media was collected from 293T packaging cells transfected
using Fugene6 reagent (Promega) in complete DMEM supplemented with
10% fetal bovine serum or in DMEM/F12 supplemented with B27 (GIBCO).
293T and SL2 cells were transfected using Fugene6 using the protocol from
TRC at the RNAi Platform of the Broad Institute of MIT and Harvard at http://
www.broadinstitute.org/rnai/public/.
shRNA Knockdown
Lentivirus was generated from pLKO.1 or pCDF (for Eya1WT and Eya1 D237A;
Wu et al., 2013), lentiviral shRNAs obtained from TRC. SL2 cells were plated in
12-well or 6-well plates, then infected with shRNA lentivirus. Infected cells
were selected with 4 mg/ml puromycin, then cells were stimulated with SAG
or vehicle (300 ng) for 48 or 72 hr before RNA or protein collection.
Quantitative Real-Time PCR
RNA was extracted using Trizol (Invitrogen) according to manufacturer’s
protocol. Reverse transcription was performed using the cDNA archive kit
(Applied Biosystems) according to the manufacturer’s specifications. Quanti-
tative real-time RT-PCR was performed using Taqman gene expression
assays to assess the expression of Eya1 Mm00438796_m1, Eya2
Mm00802561_m1, Smo Mm01162710_m1, Gli1 Mm00494645_m1, Ptch1
Mm00436026_m1, Gli2 Mm01293117_m1, Dach1 Mm00473899_m1, Dach2
Mm00473899_m1, Six1 Mm00808212_m1, Six2 Mm00807058_m1, Six4
Mm00803396_m1, Six5 Mm01305439_g1, Nrp1 Mm00435371_m1, and
Nrp2 Mm00803099_m1. Values were normalized to gapdh levels.
Western Blotting
Cells were lysed in modified radioimmunoprecipitation assay buffer, and pro-
tein lysates were separated by 4% to 12% SDS-PAGE and blotted with pri-
mary antibodies. Bandswere visualizedwith secondary antibodies conjugated
to horseradish peroxidase (1:10,000: Bio-Rad) and SuperSignal chemilumi-
nescent substrate kit. For western blot quantification, film was scanned using
Epson perfection V750 pro scanner and Epson scan software. Background-
subtracted band density was measured in ImageJ (NIH) and normalized to
actin as a loading control.32 Developmental Cell 33, 22–35, April 6, 2015 ª2015 Elsevier Inc.Immunohistochemistry and In Situ Hybridization
Immunohistochemistry and in situ hybridization were performed as described
(Chan et al., 2009). For visualization of cilia in dissociated granule cell precur-
sors, dissociated cells were stained with antibodies to acetylated alpha tubulin
(Invitrogen #322700) and to gamma tubulin (Sigma #T5192) and imaged on a
Leica confocal microscope at 633 with optical zoom (Leica Microsystems).
Images were acquired with the Leica Microsystems Application Suite (24.1
build 6384), then processed and analyzed using ImageJ software and Adobe
Photoshop 7.0. For pH3 detection, sections were dried at room temperature
for 30 to 60 min, rehydrated with PBS 23 for 5 min, and then underwent anti-
gen retrieval in Tris-EDTA antigen retrieval solution (0.005M Tris, 0.001 M
EDTA), blocked and permeabilized (3% NGS, 5% BSA, 0.3% Triton X-100)
for 1 hr. Tissue was incubated overnight at 4C with antibody in (3% NGS,
0.3% Triton). Cells in the M phase of the cell cycle were detected using mouse
anti-pH3. Primary antibody was washed, secondary antibody was applied,
and cells were mounted. pH3-positive cells were detected by immunofluores-
cence and analyzed using NIS Elements imaging software. Positive cells were
manually counted. Sections were collected from three pairs of mutant and
wild-type animals, each pair was collected from a unique litter. The detection
of apoptotic cells was conducted using DeadEnd Fluorometic TUNEL system
staining (Progema, G3250). The percentage of TUNEL-positive cells was
calculated using NIS Elements software to manually count TUNEL-positive
cells the number DAPI-positive cells. Sections were collected from three pairs
of mutant and wild-type animals, each pair was collected from a unique litter.
Antibodies
Antibodies used were Eya1 (Aviva Systems Biology #ARP32434), HA (Millipore
#05-904), actin (Cell Signaling #4968), Gli1 (Cell Signaling #2534), Six1 (Abcam
#ab84329, #ab86028), Nrp1 (R&D Systems #AF566), Nrp2 (Cell Signaling
#3366), Gli2 (Aviva Systems Biology #ARP31885), Gli3 (R&D Systems
#AF3690), gamma-tubulin (Sigma #T5192), and acetylated-alpha-tubulin
(Invitrogen #322700).
Gene Expression Analysis
Results from Affymetrix arrays of pediatric medulloblastomas (GSE37418)
were analyzed. Levels of Eya1 in samples from each of the four tumor subtypes
as defined in that study (8 Wnt, 10 Shh, 17 group 3, 39 group 4) were plotted
and analyzed in Prism by ANOVA (p < 0.0001).
Methods for Six1 ChIP-qPCR
Approximately 20 million to 80 million SL2 cells were used for a single ChIP
experiment. Cells were stimulated with SAG for 3 days, incubated with cross-
linking solution (1% formaldehyde, 100mMNaCl, 1mMEDTA [pH 8.0], 0.5mM
EGTA [pH 8.0], 50mMHEPES [pH 7.9]) for 10min at room temperature. Cross-
linking was quenchedwith 125mMglycine for 5min at room temperature, cells
were rinsed with cold PBS and resuspended in PBS with protease inhibitors.
To isolate nuclei, cell pellets were lysed in 2 mL of Buffer I (50 mM HEPES
KOH [pH 7.5], 140 mM NaCl, 1mM EDTA [pH 8.0], 10% glycerol, 0.5% NP-
40, 0.25% Triton X-100, 10 mM B-glycerophosphate, 10 mM sodium fluoride,
13 protease inhibitor cocktail, 100 nM okadaic acid) and incubated 10 min at
4C. Nuclei were then pelleted for 10 min at 4C at 3,000 rpm. Isolated nuclei
were washed in Buffer II (200 mM NaCl, 1 mM EDTA [pH 8.0], 0.5 mM EGTA
[pH 8.0], 10mMTris [pH 8.0], 10mMB-glycerophosphate, 10mMsodium fluo-
ride, 13 protease inhibitor cocktail, 100 nM okadaic acid), suspended in Buffer
III (10 mM Tris-HCl [pH 8.0], 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1%
Na-deoxycholate, 0.5% N-laurylsarcosine, 10 mM NaF, 13 protease inhibitor
cocktail, 100 nM okadaic acid). Nuclear lysates were sonicated using a
Bioruptor sonicator, for a total of 32 cycles. After sonication, samples were
centrifuged. After Triton X-100 and SDS were added, samples were incubated
for 1 hr at 95C, then incubated with proteinase K for 30 min at 55C, purified
with the Qiagen PCR purification kit.
Lysates were pre-clearedwith 15ul pre-rinsed Protein ADynabeads in 200 ml
TBSTPb (0.01% BSA and 0.2 mM PMSF in 13 TBST). Pre-cleared lysates
were incubated with Six1 Abcam antibody coupled to Protein A Dynabeads
overnight at 4C. Beads were then bound to immune complexes, collected,
and washed twice each with low-salt buffer and high-salt buffer. Immunopre-
cipitated materials were eluted twice with elution buffer (10 mM Tris-HCl
[pH 8.0], 1 mM EDTA [pH 8.0], 1% SDS) at 65C for 30 min. All eluates were
reverse-crosslinked at 65C overnight for 12 to 16 hr. RNase A was added for
1 hr at 37C, then proteinase K was added for 2 to 3 hr at 55C, and DNA was
isolated from each sample. qPCR of ChIP samples was performed for Hoxd10
as the negative region and Six4 as the positive region. Primer sequences
used were Six4_F: ATCTGGCCGATCAGGTTTC; Six4_R: ACCGGAGGAGT
CACGTTG; Hoxd10_F: GAGAAATCGGACTCACCTTCC; and Hoxd10_R:
CACATACCCAGGCAGAACG. For each primer set, we analyzed standard
curves and melting curves to assess the quality of the primers. Sequential
dilutions of input DNA were used for the qPCR standard curve.
Screen Data
See Table S5 for primary data from the phosphatome screen. The data are also
available on figshare: http://dx.doi.org/10.6084/m9.figshare.1287817.
Statistics
Within each experiment, mRNA or protein values for each condition were
normalized to an internal standard (gapdh or actin). To average results across
multiple independent experiments, values were normalized to the results ob-
tained with a control virus in that experiment (LacZ). Statistical significance
was determined using a Z test with Bonferroni correction for multiple compar-
isons, or by Student’s t test with Bonferroni correction in Microsoft Excel, or by
ANOVA with Tukey’s post-test analysis in Prism (GraphPad Software) as indi-
cated. All experiments were done with at least three independent biological
replicates.
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